Pharmacotherapy Management of Alzheimer’s Disease (AD)
Management of patients with Alzheimer’s Disease (AD) focuses primarily on symptom management but new disease modifying therapies have entered the market. This presentation will review current treatment options for different AD stages and include review of the new treatments and their place in therapy. This activity will focus on a practical approach to pharmacotherapy management of a patient with AD and information needed to provide up to date care and counseling. An overview of the management of patients with AD including the new monoclonal antibodies, with emphasis on lecanemab and including its incorporation in the practice.
Note
This course is NOT FL Consultant Approved.
Learning Objectives
At the conclusion of this application-based activity, participants should be able to:
- Recall major pathological hallmarks of Alzheimer’s disease (AD).
- Describe the AD continuum and clinical presentation.
- Discuss current pharmacotherapy options and their place in AD therapy.
- Given a patient case, provide a pharmacotherapy treatment plan for AD.
Target Audience
Senior Care Pharmacists who provide expert advice on the use of medications to individuals and older adults and are committed to providing person-centered care, considering the complex interrelationships between disease states, nutrition, medications, and other variables.
Speaker
Marketa Marvanova , PharmD, PhD, BCGP, BCPP, FASCP
Dean and Professor
Pacific University School of Pharmacy
Financial Disclosure
Antimicrobial Resistance Solutions, Inc. – Co-owner/employee
Indiana Department of Health – ARS as contractor/grant funding
None of the planners for this activity has relevant financial relationships with ineligible companies to disclose.
How to Access Content
-
Once you have purchased/enrolled in an activity, select “Launch”, at the top of the activity information page to open the course.
- Click through the left-hand menu items, in sequence, to progress through the course. You must complete the course in its entirety to claim credit.
-
Post-test must be completed, with minimum score of 75%, before moving on to the evaluation.
-
All courses contain an evaluation that must be completed for full CPE credit by expiration date. No exceptions or extensions permitted.
-
If you need assistance, email the Education Department at
education@ascp.com
Claim Credit
UAN: 0203-9999-24-047-H01-P
Date of Release: 08/01/2024
Date of Expiration: 08/01/2025, 11:59pm ET
BCGP Pharmacists: To ensure successful transfer of BCGP credit, your ASCP profile must be updated with your correct BCGP Credential Number and BPS-IND# prior to course completion. *Please note, any edit/updates made to your BCGP credential information in your ASCP profile after course completion requires a re-push, please submit your completed transcript to education@ascp.com for a manual upload.
CPE & BCGP Credit: You must complete the post-test and evaluation by the expiration date to receive credit. You have three attempts to achieve a 75% or higher on the post-test. ASCP reports CPE attainment to ACPE and NABP via the CPE Monitor system. The course should be posted within 24-48 hours of evaluation completion. The participant is responsible for providing their correct date of birth (MMDD format) and NABP e-Profile ID on their member or guest profile on the ASCP Website.
Accreditation
ASCP is approved by BPS as a provider for the recertification of BCGP.
The American Society of Consultant Pharmacists (ASCP) is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education.
This educational activity was developed by the American Society of Consulting Pharmacists (ASCP) in collaboration with the American Pharmacists Association (APhA). To study a case about this topic through APhA, please visit the catalog to learn more. ASCP members will receive the APhA member rate when using this code: ASCPMBR